(1-oxy-[3]pyridyl)-acetic acid | 67445-83-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (1-oxy-[3]pyridyl)-acetic acid
• 英文别名: (1-Oxy-[3]pyridyl)-essigsaeure；3-Pyridineaceticacid,1-oxide；2-(1-oxidopyridin-1-ium-3-yl)acetic acid
• CAS: 67445-83-4
• 化学式: C₇H₇NO₃
• 分子量: 153.137
• InChiKey: BEKIXDAHVQCUGC-UHFFFAOYSA-N

物化性质

• 熔点：
  142-144 °C (decomp)(Solv: ethyl acetate (141-78-6); ethanol (64-17-5))
• 沸点：
  445.9±20.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1-oxy-[3]pyridyl)-acetic acid 、 3,5-二叔丁基-4-羟基苯甲醛 在 哌啶 作用下， 以 二氯甲烷 为溶剂， 生成 2,6-ditert-butyl-4-[(E)-2-(1-oxidopyridin-1-ium-3-yl)ethenyl]phenol
  参考文献：
  名称：

  Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols

  摘要：

  A series of 2,6-di-tert-butyl-4-(2-arylethenyl)phenols was prepared and examined for their ability to inhibit cyclooxygenase and 5-lipoxygenase in vitro and developing adjuvant arthritis in vivo in the rat. Structure-activity relationships are discussed. Among the best compounds is (E)-2,6-di-tert-butyl-4-[2-(3-pyridinyl)ethenyl]phenol (7d). It has an IC50 of 0.67 microM for cyclooxygenase and 2.7 microM for 5-lipoxygenase and an ED50 of 2.1 mg/kg in developing adjuvant arthritis. Additional in vivo data are reported for 7d.

  DOI：

  10.1021/jm00121a021
• 作为产物：
  描述：

  3-吡啶乙酸乙酯 在 氢氧化钾 、 双氧水 、 溶剂黄146 作用下， 生成 (1-oxy-[3]pyridyl)-acetic acid
  参考文献：
  名称：

  31. N-氧化物和相关化合物。第七部分 一些共轭吡啶的过酸氧化

  摘要：

  DOI：

  10.1039/jr9580000150

文献信息

• Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
  申请人：——

  公开号：US20030055065A1

  公开（公告）日：2003-03-20

  A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: 1 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of the formulas 2 are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

  本发明揭示了一种抑制Ras功能，从而抑制细胞异常生长的方法。该方法包括向生物系统中给予1.0:1式化合物。特别是，该方法抑制哺乳动物（如人类）中细胞的异常生长。本发明还揭示了新的2式化合物。还揭示了制备5.0、5.1、5.2和5.3式3-取代化合物的方法。本发明还揭示了制备3-取代化合物5.0、5.1、5.2和5.3式的中间体。
• Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
  申请人：SCHERING CORPORATION

  公开号：EP1123931A1

  公开（公告）日：2001-08-16

  A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of formula (1.0) to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulae (5.0, 5.1, 5.2, 5.3, 5.3A and 5.3B) are disclosed. Also disclosed are process for making the 3-substituted compound of formulae (5.0, 5.1, 5.2 and 5.3). Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of formulae (5.0, 5.1, 5.2 and 5.3).

  本发明公开了一种抑制 Ras 功能从而抑制细胞异常生长的方法。该方法包括向生物系统施用式（1.0）化合物。特别是，该方法可抑制哺乳动物如人体内细胞的异常生长。本发明公开了式(5.0、5.1、5.2、5.3、5.3A 和 5.3B)的新型化合物。还公开了式 (5.0、5.1、5.2 和 5.3) 的 3-取代基化合物的制造工艺。还公开了作为式（5.0、5.1、5.2 和 5.3）3-取代化合物制造工艺中间体的新型化合物。
• Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5<i>H</i>-benzo[5,6]- cyclohepta[1,2-<i>b</i>]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11- dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridin-11-yl)piperazine
  作者：Alan K. Mallams、Randall R. Rossman、Ronald J. Doll、Viyyoor M. Girijavallabhan、Ashit K. Ganguly、Joanne Petrin、Lynn Wang、Robert Patton、W. Robert Bishop、Donna M. Carr、Paul Kirschmeier、Joseph J. Catino、Matthew S. Bryant、Kwang-Jong Chen、Walter A. Korfmacher、Cymbelene Nardo、Shiyong Wang、Amin A. Nomeir、Chin-Chung Lin、Zujun Li、Jianping Chen、Suining Lee、Janet Dell、Philip Lipari、Michael Malkowski、Bodan Yaremko、Ivan King、Ming Liu

  DOI：10.1021/jm970462w

  日期：1998.3.1

  The synthesis of a variety of novel 4-amido, 4-carbamoyl and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin -11-yl)piperazine to explore the SAR of of this series of FPT inhibitors is described. This resulted in the synthesis of the 4- and 3-pyridylacetyl analogues 45a and 50a, respectively, both of which were orally active but were found to be rapidly metabolized in vivo. Identification of the principal metabolites led to the synthesis of a variety of new compounds that would be less readily metabolized, the most interesting of which were the 3- and 4-pyridylacetyl N-oxides 80a and 83a. Novel replacements for the pyridylacetyl moiety were also sought, and this resulted in the discovery of the 4-N-methyl and 4-N-carboxamidopiperidinylacetyl derivatives 135a and 160a, respectively. All of these derivatives exhibited greatly improved pharmacokinetics. The synthesis of the corresponding 3-bromo analogues resulted in the discovery of the 4-pyridylacetyl N-oxides 83b (+/-) and 85b [11S(-)] and the 4-carboxamidopiperidinylacetamido derivative 160b (+/-), all of which exhibited potent FPT inhibition in vitro. All three showed excellent oral bioavailability in vivo in nude mice and cynomolgus monkeys and exhibited excellent antitumor efficacy against a series of tumor cell lines when dosed orally in nude mice.
• TRICYCLIC AMIDE AND UREA COMPOUNDS USEFUL FOR INHIBITION OF G-PROTEIN FUNCTION AND FOR TREATMENT OF PROLIFERATIVE DISEASES
  申请人：SCHERING CORPORATION

  公开号：EP0723540A1

  公开（公告）日：1996-07-31
• US5700806A
  申请人：——

  公开号：US5700806A

  公开（公告）日：1997-12-23